New hope for melanoma patients who Don't respond to standard immunotherapy
NCT ID NCT06999980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their tumor is removed. The main goal is to see if these treatments can shrink or eliminate the cancer by the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Melanoma Institute Australia
RECRUITINGWollstonecraft, New South Wales, 2065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- E-Learning could sharpen Doctors' eye for skin cancer
- Can a new drug tame advanced solid tumors?
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?